Results 1 to 10 of about 584 (117)

C-type lectin receptor agonists elicit functional IL21-expressing Tfh cells and induce primary B cell responses in neonates [PDF]

Frontiers in Immunology, 2023
IntroductionC-type lectin receptor (CLR) agonists emerged as superior inducers of primary B cell responses in early life compared with Toll-like receptor (TLR) agonists, while both types of adjuvants are potent in adults.MethodsHere, we explored the ...
Maria Vono, Beatris Mastelic-Gavillet, Elodie Mohr, Malin Östensson, Josefine Persson, Thorunn A. Olafsdottir, Sylvain Lemeille, David Pejoski, Oliver Hartley, Dennis Christensen, Peter Andersen, Arnaud M. Didierlaurent, Ali M. Harandi, Ali M. Harandi, Paul-Henri Lambert, Claire-Anne Siegrist   +15 more
doaj   +2 more sources

Mincle-dependent Th17 adjuvanticity requires TNFR1 signaling in myeloid cells [PDF]

Frontiers in Immunology
Successful induction of protective T cells by recombinant protein vaccines requires adjuvants. The liposomal adjuvant system CAF01 induces robust Th17 responses in mice.
Robert Blamberg, Carl Haberkamp, Gabriel Kristian Pedersen, Ida Rosenkrands, Ulrike Schleicher, Ulrike Schleicher, Barbara U. Schraml, Sho Yamasaki, Roland Lang, Roland Lang   +9 more
doaj   +2 more sources

Heterologous prime-boost immunization combining parenteral and mucosal routes with different adjuvants mounts long-lived CD4+ T cell responses in lungs [PDF]

Frontiers in Immunology
IntroductionAirway mucosa represents the main entry point for several human pathogens, and as such vaccines against respiratory diseases should ideally elicit protective immune responses in the airways.
Ranmali Kavishna, Thorunn Asta Olafsdottir, Siggeir F. Brynjólfsson, Dennis Christensen, Tobias Gustafsson-Hedberg, Peter Andersen, Manuela Terrinoni, Jan Holmgren, Ali M. Harandi, Ali M. Harandi   +9 more
doaj   +2 more sources

Liposomal delivery system/adjuvant for tuberculosis vaccine. [PDF]

Immun Inflamm Dis, 2023
The delivery system and safety regulator are common characteristics of effective adjuvants in tuberculosis (TB) vaccines and the clinical trial stage. Based on our findings, the liposomal system is a superb adjuvant for vaccinations against TB, other intracellular infections, and malignancies.
Moradi M, Vahedi F, Abbassioun A, Ramezanpour Shahi A, Sholeh M, Taheri-Anganeh M, Dargahi Z, Ghanavati R, Khatami SH, Movahedpour A.   +9 more
europepmc   +2 more sources

Dose-sparing effects of novel adjuvants and aluminum hydroxide on two different vaccines in a neonatal mouse model [PDF]

Frontiers in Immunology
Childhood vaccination provides protection against infectious diseases, but multiple vaccinations are required to achieve this. In situations like influenza epidemics or COVID-19 pandemic, vaccine demands may exceed production capacity, highlighting the ...
Jenny Lorena Molina Estupiñan, Jenny Lorena Molina Estupiñan, Poorya Foroutan Pajoohian, Poorya Foroutan Pajoohian, Gabriel Kristian Pedersen, Dennis Christensen, Serena Marchi, Emanuele Montomoli, Emanuele Montomoli, Stefanía P. Bjarnarson, Stefanía P. Bjarnarson, Ingileif Jonsdottir, Ingileif Jonsdottir, Audur Anna Aradottir Pind, Audur Anna Aradottir Pind   +14 more
doaj   +2 more sources

Sublingual Boosting with a Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as a Strategy Against Chlamydia trachomatis. [PDF]

Adv Healthc Mater, 2022
The optimal thermosensitive, mucoadhesive and stable hydrogel (OGEL) developed through artificial intelligence tools within the concept of “Quality by Design” is useful as a carrier for chlamydia subunit vaccine CTH522. The sublingual administration of OGEL/CTH522, after parenteral immunization with CAF01/CTH522 (cationic liposomes), promotes Th1&Th17 ...
Garcia-Del Rio L, Diaz-Rodriguez P, Pedersen GK, Christensen D, Landin M.   +4 more
europepmc   +2 more sources

CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets [PDF]

PLoS ONE, 2011
Trivalent inactivated vaccines (TIV) against influenza are given to 350 million people every year. Most of these are non-adjuvanted vaccines whose immunogenicity and protective efficacy are considered suboptimal. Commercially available non-adjuvanted TIV
Trine Hammer Jensen, Peter Andersen, Lars Andresen   +2 more
exaly   +2 more sources

Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone

Frontiers in Immunology, 2020
Understanding the in vivo fate of vaccine antigens and adjuvants and their safety is crucial for the rational design of mucosal subunit vaccines. Prime and pull vaccination using the T helper 17-inducing adjuvant CAF01 administered parenterally and ...
Harald S Hansen, Fernanda Endringer Pinto, Christian Janfelt   +2 more
exaly   +3 more sources

Physiologically Based Pharmacokinetic Modeling of Caffeine in Preterm Neonates: Influence of Renal Function and Impairment on Dosing. [PDF]

J Clin Pharmacol
Abstract Currently, the same weight‐based caffeine citrate dosing regimen is applied to all neonates. However, due to differences in growth trajectories by gestational age (GA) and altered caffeine elimination in neonates with renal injury, optimal dosing regimens may differ. In this study, we refined the existing physiologically based pharmacokinetic (
Thomas N, Harer MW, Lim SY.
europepmc   +2 more sources

Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01 [PDF]

PLoS ONE, 2014
The development of new low cost inactivated polio virus based vaccines (IPV) is a high priority, and will be required to eradicate polio. In addition, such a vaccine constitutes the only realistic polio vaccine in the post-eradication era.
Jes Dietrich, Peter Andersen, Else Marie Agger   +2 more
exaly   +2 more sources